PALO ALTO, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Gaurav Aggarwal, M.D., chief business officer, will be presenting at the JMP Securities Life Sciences Conference being held at The St. Regis in New York City, NY. Ocera's presentation is scheduled for Wednesday, June 24, 2015 at 10:00 AM Eastern Time in the Fontainebleau conference room.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 30 days following the conference for those unable to listen live.
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
Susan Sharpe Ocera Therapeutics, Inc. firstname.lastname@example.org 919-328-1109
Source:Ocera Therapeutics, Inc.